Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)

Trial Details

NCT ID

NCT06610734

Phase

PHASE2

Sponsor

Sichuan University

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

• Adebrelimab
• Chemotherapy
• low dose radiotherapy

Locations (sample)

• Sichuan, China|35.1221,105.48032

Key Eligibility Criteria

• Participants aged 18 to 75 years, regardless of gender;
• ECOG Performance Status (PS) score of 0-1;
• Expected survival duration of no less than 8 weeks;
• Histologically or cytologically confirmed extensive small cell lung cancer (according to the VALG staging system);

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.